Dr. Sachin Suryawanshi is the director of medical services for the India business at Emcure Pharmaceuticals Ltd., where he plays a key role in strengthening the organization’s medical affairs, clinical engagement, and scientific communication across therapeutic areas. In this capacity, he works closely with healthcare professionals, research institutions, and internal medical teams to ensure that scientific evidence, clinical insights, and patient-focused approaches guide the company’s pharmaceutical initiatives in India.

As part of the leadership team within Emcure’s India business, Dr. Suryawanshi contributes to the development of medical strategies that support responsible pharmaceutical innovation and effective therapy adoption. His work focuses on bridging the gap between clinical science and patient care by supporting evidence-based medicine, clinical research initiatives, and medical education programs for healthcare practitioners. Through these efforts, he helps strengthen the scientific credibility and therapeutic value of the company’s products across key disease areas.

Dr. Suryawanshi is also actively engaged in academic and scientific collaborations, contributing to medical research and publications addressing critical health challenges. His involvement in clinical studies and scientific literature reflects a broader commitment to advancing medical knowledge and improving treatment outcomes for patients, particularly in areas such as cardiovascular health and related disorders.

Emcure Pharmaceuticals, headquartered in Pune, is a global pharmaceutical company with a presence in more than 70 countries and a diverse portfolio spanning cardiology, gynecology, oncology, infectious diseases, and biotechnology. The company is recognized for its strong focus on research, innovation, and the development of affordable medicines that improve patient outcomes worldwide.

Through his leadership in medical services and his dedication to clinical excellence, Dr. Sachin Suryawanshi continues to support Emcure’s mission of advancing evidence-based healthcare while strengthening the integration of scientific research, medical practice, and patient-centric pharmaceutical innovation.